We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noninvasive Device Measures Hemoglobin More Accurately in Individuals with Darker Skin Pigmentations

By LabMedica International staff writers
Posted on 31 Oct 2022
Print article
Image: New tech aims to reduce racial disparities in blood measurements (Photo courtesy of University of Texas at Arlington)
Image: New tech aims to reduce racial disparities in blood measurements (Photo courtesy of University of Texas at Arlington)

Racial disparities in hemoglobin and blood oxygen measurements are an urgent public health issue. The devices presently in use are inaccurate in people with dark skin. Most methods for monitoring hemoglobin require blood samples and expensive equipment. Currently available pulse-oximeters use red-infrared light and are based on technology first designed more than 50 years ago. The available noninvasive spectroscopic methods have a high degree of variability and often are inaccurate in people of color due to differences in skin melanin. There is a significant unmet need for a reliable, noninvasive device to estimate hemoglobin, irrespective of skin color. Now, researchers have demonstrated a new device that measures hemoglobin more accurately in individuals with darker skin pigmentations by using the spectroscopic properties of hemoglobin in the blue-green light spectra.

In a clinical study, a team of researchers at the University of Texas at Arlington (Arlington, TX, USA) along with Shani Biotechnologies LLC (Austin, TX, USA) measured the hemoglobin and oxygen content of 16 healthy volunteers using the newly developed technology. The team compared the results to those obtained using a commercially available pulse-oximeter for accuracy and variability. The findings of the study are encouraging, and the new technology has massive potential to address this clinical unmet need. The researchers intend to develop a wearable device, such as a watch or a monitor, that would read the blood through the skin.

“We have used the green-blue light and have successfully tested the device in preclinical and clinical studies,” said Dr. Vinoop Daggubati of Shani Biotechnologies LLC. “Our group has addressed the issues around shorter wavelength, scattering of light and the impact of skin melanin. The scientific community should open its mind to the concept of green light for these measurements. The Shani device has huge potential to eliminate this racial disparity.”

Related Links:
University of Texas at Arlington 
Shani Biotechnologies 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.